Standex International (SXI)
NYSE:SXI
Want to see SXI full AI Analyst Report?
Top Page
Standex International
(NYSE:SXI)
Select Model
Select Model
Rating:69Neutral
Price Target:
$272.00
▼(-2.30% Downside)
Action:Reiterated
Date:05/04/26
The score is driven primarily by solid financial performance (healthy margins and improved scale, but leverage and cash-conversion quality remain key constraints). Valuation is supportive with a low P/E, while the latest earnings call adds confidence via positive growth outlook and backlog/new-product momentum. Technicals are the main drag due to the stock trading below key moving averages with weak momentum readings.
Positive Factors
Improved Profitability and Revenue Step‑up
A material step‑up in TTM revenue with sustained gross and net margins implies stronger operating scale and product mix. Durable margin levels near 40% gross suggest structural cost control and pricing power across engineered products, supporting multi‑period profitability.
Negative Factors
Elevated Leverage
Material outstanding debt and leverage constrain financial flexibility and increase interest burden risk. Even with recent paydowns, elevated leverage limits capacity for opportunistic investment or rapid deleveraging, making results more sensitive to slower cash conversion or market downturns.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved Profitability and Revenue Step‑up
A material step‑up in TTM revenue with sustained gross and net margins implies stronger operating scale and product mix. Durable margin levels near 40% gross suggest structural cost control and pricing power across engineered products, supporting multi‑period profitability.
Read all positive factors
Standex International (SXI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.01B
Dividend Yield0.57%
Average Volume (3M)143.50K
Price to Earnings (P/E)11.5
Beta (1Y)1.13
Revenue Growth18.33%
EPS Growth61.06%
CountryUS
Employees3,700
SectorIndustrials
Sector Strength72
IndustryIndustrial - Machinery
Share Statistics
EPS (TTM)8.24
Shares Outstanding12,114,922
10 Day Avg. Volume174,098
30 Day Avg. Volume143,496
Financial Highlights & Ratios
PEG Ratio-1.36
Price to Book (P/B)2.62
Price to Sales (P/S)2.36
P/FCF Ratio45.24
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue3.86
Enterprise Value/Gross Profit9.70
Enterprise Value/Ebitda19.10
Forecast
1Y Price Target
$298.50Price Target Upside7.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)8.72
Revenue Forecast (FY)$893.37M
Standex International Business Overview & Revenue Model
Company Description
Standex International Corporation, together with subsidiaries, manufactures and sells various products and services for commercial and industrial markets in the United States and internationally. It operates through five segments: Electronics, Eng...
How the Company Makes Money
Standex primarily makes money by selling manufactured products and engineered solutions to business customers (B2B) across its operating segments. Revenue is generated through (1) product sales of engineered components and subsystems (e.g., electr...
Standex International Earnings Call Summary
Earnings Call Date:Apr 30, 2026
(Q3-2026)
| % Change Since: |
Next Earnings Date:Jul 30, 2026
Earnings Call Sentiment Positive
The call conveyed predominantly positive operational and financial momentum: strong top‑line growth (8.1% overall), record Electronics revenue, robust Aerospace & Defense expansion, accelerating new product sales (≈40% growth) and meaningful balance sheet improvement via the Federal divestiture and $62 million debt paydown. Offsetting items are modest: margin compression in parts of Electronics and Aerospace & Defense due to growth investments, a small revenue decline in Scientific tied to NIH cuts, organic softness in Hydraulics, and increased near‑term capex and operating cost investments. Overall, the positives (revenue growth, product pipeline, book‑to‑bill >1, debt reduction, improved EPS and FCF) materially outweigh the contained challenges and investments.Positive Updates
Top-line Growth
Total sales increased 8.1% year‑on‑year to $224.6 million, including 6.5% organic growth.
Negative Updates
Segment Margin Pressures from Growth Investments
Electronics adjusted operating margin decreased 50 basis points year‑on‑year to 29.3% and Aerospace & Defense margin decreased 60 basis points to 18%, with declines attributed to growth investments and project mix.
Read all updates
Q3-2026 Updates
Positive
Negative
Top-line Growth
Total sales increased 8.1% year‑on‑year to $224.6 million, including 6.5% organic growth.
Read all positive updates
Company Guidance
Standex said it expects fiscal Q4 2026 revenue to be slightly to moderately higher sequentially (and slightly to moderately higher year‑over‑year), driven by mid‑ to high‑single‑digit organic growth, stronger backlog in fast‑growth markets and increased new‑product sales; sequential adjusted operating margin is expected to be slightly to moderately higher, but year‑over‑year Q4 margin is expected to be slightly lower as growth investments, higher medical costs and increased variable compensation more than offset productivity gains. For full‑year 2026 the company still expects revenue to increase by about $100 million versus 2025 with margin expansion, will launch more than 15 new products (on top of 16 last year), and expects pro forma new‑product sales to rise by $24 million to $64 million (adding ~300 basis points of organic growth) and sales into fast‑growth markets to reach roughly $270 million (about 30% of total). Liquidity/capital guidance includes Q4 interest expense of $6.8–7.0 million, FY2026 capital expenditures of $27–30 million, available liquidity of ~ $191 million, cash of $103.7 million, long‑term debt of $472.8 million and net debt of $369.1 million (net leverage ~1.9x after using roughly $62 million of Federal divestiture proceeds from a ~ $70 million enterprise value sale); Q3 operating context: revenue $224.6 million (+8.1% YoY; 6.5% organic), adjusted operating margin 19.7% (+30 bps), adjusted EPS $2.21 (+13.5%), free cash flow $6.3 million, Electronics revenue $119.7 million (book‑to‑bill 1.14; orders ≈ $136 million) and Aerospace & Defense revenue $36.6 million (organic +20.8%).Standex International Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
64
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 885.39M | 790.11M | 720.63M | 741.05M | 735.34M | 656.23M |
| Gross Profit | 352.44M | 300.64M | 282.00M | 285.10M | 269.95M | 241.26M |
| EBITDA | 178.95M | 128.18M | 121.92M | 141.85M | 129.71M | 111.44M |
| Net Income | 98.98M | 55.76M | 73.07M | 138.99M | 61.39M | 36.47M |
Balance Sheet | ||||||
| Total Assets | 1.53B | 1.57B | 1.01B | 1.02B | 934.44M | 962.22M |
| Cash, Cash Equivalents and Short-Term Investments | 103.72M | 104.54M | 154.20M | 195.71M | 104.84M | 136.37M |
| Total Debt | 509.43M | 603.70M | 187.89M | 207.25M | 214.08M | 236.46M |
| Total Liabilities | 728.37M | 827.29M | 383.55M | 417.48M | 435.10M | 455.80M |
| Stockholders Equity | 754.18M | 711.68M | 621.50M | 607.45M | 499.34M | 506.43M |
Cash Flow | ||||||
| Free Cash Flow | 54.27M | 41.25M | 72.36M | 66.53M | 53.83M | 61.83M |
| Operating Cash Flow | 79.58M | 69.60M | 92.66M | 90.80M | 77.72M | 83.58M |
| Investing Cash Flow | 41.06M | -503.43M | -61.63M | 41.56M | -31.04M | -39.09M |
| Financing Cash Flow | -127.77M | 380.49M | -69.20M | -40.04M | -69.43M | -31.73M |
Standex International Technical Analysis
Positive
278.40
Price Trends
258.62
Positive
247.94
Positive
225.95
Positive
Market Momentum
4.76
Negative
64.01
Neutral
77.05
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SXI, the sentiment is Positive. The current price of 278.4 is above the 20-day moving average (MA) of 261.73, above the 50-day MA of 258.62, and above the 200-day MA of 225.95, indicating a bullish trend. The MACD of 4.76 indicates Negative momentum. The RSI at 64.01 is Neutral, neither overbought nor oversold. The STOCH value of 77.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SXI.
Standex International Risk Analysis
Standex International disclosed 26 risk factors in its most recent earnings report. Standex International reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Standex International Peers Comparison
UnderperformOutperform
Sector (63)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $2.55B | 28.26 | 5.33% | 0.64% | 10.45% | 64.56% | |
69 Neutral | $3.01B | 11.46 | 13.78% | 0.57% | 18.33% | 61.06% | |
64 Neutral | $4.46B | -100.63 | -18.89% | ― | 29.10% | -3.32% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
57 Neutral | $1.40B | -36.68 | -60.13% | ― | 5.96% | -37.16% | |
53 Neutral | $1.73B | 32.79 | 20.01% | 0.10% | 4.23% | -5.90% |
* Industrials Sector Average
SXI
Standex International
248.69
93.29
60.03%
EPAC
Enerpac Tool Group
33.65
-11.65
-25.72%
ENOV
Enovis
24.29
-11.19
-31.54%
HLIO
Helios Technologies
77.03
44.56
137.26%
XMTR
Xometry
86.12
52.02
152.55%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.